Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid

NCT01283581 is registered in ClinicalTrials.gov with Melinta Therapeutics, Inc. as lead sponsor.

NCT NCT01283581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01283581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Lead sponsor
Melinta Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
November 30, 2011
Enrollment
256 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

skin and subcutaneous tissue bacterial infections